lacidipine (motens) Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Lacidipine is a calcium channel blocker. It is available as tablets containing 2 or 4 mg.   Wikipedia

Chemistry

  • SMILES: CCOC(=O)C1=C(C)NC(=C(C1c2ccccc2\C=C\C(=O)OC(C)(C)C)C(=O)OCC)C
  • InChIKey: GKQPCPXONLDCMU-CCEZHUSRSA-N
  • Mol. Mass: 455.55
  • ALogP: 4.4
  • ChEMBL Molecule:
    lacidipine  
More Chemistry

Pharmacology

Alternative names

boehringer ingelheim brand of lacidipine | caldine | diethyl 2,6-dimethyl-4-(2-((e)-2-((2-methylpropan-2-yl)oxycarbonyl)ethenyl)phenyl)-1,4-dihydropyridine-3,5-dicarboxylate | glaxosmithkline brand of lacidipine | gr 43659x | gr-43659x | lacidipine | lacimen | lacipil | lacirex | menarini brand of lacidipine | molap | motens

Organizations (4)

Research & Development (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (5)

Approved Indications (1)


 

Hypertension

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Angina Pectoris (Phase 2)

Diabetes Mellitus, Type 2 (Phase 4)

Essential Hypertension (Phase 4)

Healthy Volunteers (Phase 1)

Hypertension (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 11
  • # of Trial Organizations: 4

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue